The company has an early stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms) and ocular hypertension.
Location: United Kingdom, England, Norwich
Employees: 1-10
Total raised: $3.249285M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 14.09.2021 | Future Pla... | futureplan... |
| - | Life Arc V... | lifearcven... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 05.02.2020 | Seed | $3.249285M | - | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 05.02.2020 | Ophthalmic gene therapy company Ikarovec launches with £2.5m... | Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has launch... | cambridgen... |
| 05.02.2020 | Ikarovec Raises £2.5M in Seed Funding | Ikarovec, a Cambridge, UK-based ophthalmic gene therapy company, raised £2.5m in seed funding. Back... | finsmes.co... |
| 05.02.2020 | Ophthalmic gene therapy company Ikarovec launches with £2.5m... | Ophthalmic gene therapy company Ikarovec launches with £2.5m seed funding 05-02-2020 Ikarovec, whi... | cambridgen... |